NEURACEQ Drug Patent Profile
✉ Email this page to a colleague
When do Neuraceq patents expire, and what generic alternatives are available?
Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-four patent family members in twenty-six countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Neuraceq
Neuraceq was eligible for patent challenges on March 21, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 18, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NEURACEQ
International Patents: | 34 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 6 |
Patent Applications: | 101 |
What excipients (inactive ingredients) are in NEURACEQ? | NEURACEQ excipients list |
DailyMed Link: | NEURACEQ at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NEURACEQ
Generic Entry Date for NEURACEQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NEURACEQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Life Molecular Imaging GmbH | Phase 3 |
William Charles Kreisl | Phase 1/Phase 2 |
Ulsan University Hospital | N/A |
US Patents and Regulatory Information for NEURACEQ
NEURACEQ is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NEURACEQ is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NEURACEQ
Stilbene derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEURACEQ
When does loss-of-exclusivity occur for NEURACEQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 05316421
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0516408
Estimated Expiration: See Plans and Pricing
Canada
Patent: 91534
Estimated Expiration: See Plans and Pricing
China
Patent: 1123995
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 06
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 13652
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 2334
Estimated Expiration: See Plans and Pricing
Patent: 0701299
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 38298
Estimated Expiration: See Plans and Pricing
Patent: 41465
Estimated Expiration: See Plans and Pricing
Patent: 13652
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 500014
Estimated Expiration: See Plans and Pricing
Israel
Patent: 3946
Estimated Expiration: See Plans and Pricing
Patent: 6091
Estimated Expiration: See Plans and Pricing
Japan
Patent: 28956
Estimated Expiration: See Plans and Pricing
Patent: 08524243
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 213652
Estimated Expiration: See Plans and Pricing
Luxembourg
Patent: 647
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 07007380
Estimated Expiration: See Plans and Pricing
Netherlands
Patent: 0719
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 5942
Estimated Expiration: See Plans and Pricing
Norway
Patent: 9195
Estimated Expiration: See Plans and Pricing
Patent: 073650
Estimated Expiration: See Plans and Pricing
Poland
Patent: 13652
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 13652
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 4363
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 13652
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 0705104
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1321619
Estimated Expiration: See Plans and Pricing
Patent: 070093427
Estimated Expiration: See Plans and Pricing
Spain
Patent: 26655
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 996
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NEURACEQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101321619 | See Plans and Pricing | |
European Patent Office | 2213652 | Dérivés de stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et leur liaison (Stilbene derivatives and their use for binding and imaging amyloid plaques) | See Plans and Pricing |
Japan | 5128956 | See Plans and Pricing | |
Hungary | S1500014 | See Plans and Pricing | |
Japan | 4950031 | See Plans and Pricing | |
Netherlands | 300719 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NEURACEQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2213652 | SPC/GB15/010 | United Kingdom | See Plans and Pricing | PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224 |
2213652 | PA2015005 | Lithuania | See Plans and Pricing | PRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220 |
2213652 | 132015902339134 | Italy | See Plans and Pricing | PRODUCT NAME: FLORBETABEN (18)(NEURACEQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/906, 20140224 |
2213652 | C02213652/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66210 23.08.2017 |
2213652 | 8/2015 | Austria | See Plans and Pricing | PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224 |
2213652 | 92647 | Luxembourg | See Plans and Pricing | PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |